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SUMMARY
Alzheimer’s disease is the world’s most common
neurodegenerative disorder. It is associated with
neuroinflammation involving activation of microglia
by b-amyloid (Ab) deposits. Based on previous
studies showing apoptosis-associated speck-like
protein containing a CARD (ASC) binding and
cross-seeding extracellular Ab, we investigate the
propagation of ASC between primary microglia and
the effects of ASC-Ab composites on microglial
inflammasomes and function. Indeed, ASC released
by a pyroptotic cell can be functionally built into the
neighboring microglia NOD-like receptor protein
(NLRP3) inflammasome. Compared with protein-
only application, exposure to ASC-Ab composites
amplifies the proinflammatory response, resulting in
pyroptotic cell death, setting free functional ASC
and inducing a feedforward stimulating vicious cycle.
Clustering around ASC fibrils also compromises
clearance of Ab by microglia. Together, these data
enable a closer look at the turning point from acute
to chronic Ab-related neuroinflammation through
formation of ASC-Ab composites.
INTRODUCTION
Alzheimer’s disease (AD) is the most common dementing illness,
characterized by progressive memory decline and cognitive
dysfunction (Zverova´, 2019). The pathological hallmarks of AD
are deposition of extracellular b-amyloid (Ab) and intraneuronal
aggregation of neurofibrillary tangles composed of the microtu-
bule-associated protein tau (Nelson et al., 2012). Under healthy
conditions, the balance of Ab and tau deposition and clearance
is maintained by brain-resident microglia. However, in the AD
brain, this equilibrium is shifted toward protein deposition (Sarlus
and Heneka 2017; Heneka et al. 2015).
As resident immune effector cells of the CNS, microglia play a
crucial role in mediating brain homeostasis and the innate
immune response against a wide range of pathogenic factors
(Clayton et al., 2017; Hanisch and Kettenmann, 2007). Microglia
sense a variety of microbial molecules called pathogen-associ-
ated molecular patterns (PAMPs) but also host-derived
danger-associated molecular patterns (DAMPs) by pattern
recognition receptors (PRRs). PRR ligation then fuels signaling
transduction pathways that induce an inflammatory response
and also lead to clearance of debris by phagocytosis (Heneka
et al., 2014). Recognition of oligomeric of fibrillar Ab, which either
serves as a PAMP or a DAMP (Terrill-Usery et al., 2014), rapidly
triggers NLRP3 inflammasome activation (Halle et al., 2008;
Kinney et al., 2018). Furthermore, NLRP3 inflammasome activa-
tion relies on two signals: transcriptional upregulation of inflam-
masome components via the transcription factor nuclear factor
kB (NF-kB) (Kawai and Akira, 2010) and a second signal gener-
ated by DAMP-induced ion fluxes, mitochondrial reactive
oxygen species (ROS) production, or lysosomal destabilization,
which, in turn, leads to assembly and activation of the inflamma-
some (Yang et al., 2019).
The NLRP3 inflammasome is a multiprotein complex in which
the receptor protein NLRP3 is bridged to the zymogen pro-cas-
pase-1 via the adaptor protein apoptosis-associated speck-like
protein containing a CARD (ASC). Upon dimerization, caspase-1
becomes activated by auto-processing, which, in turn, leads to
cleavage of pro-inflammatory cytokines such as pro-inter-
leukin-1b (pro-IL-1b) and pro-IL-18 (Boucher et al., 2018).
In addition, caspase-1 cleaves Gasdermin D (GSDMD), a pyrop-
tosis executioner protein (Bergsbaken et al., 2009), resulting in
formation of pores in the plasma membrane and leading to cell
lysis because of ion flux and subsequent cytosolic swelling (Liu
et al., 2016). Moreover, GSDMD-induced pore-formation results
in release of IL-1b into the extracellular space (Rathinam et al.,
2019).
The adaptor protein ASC is composed of a N-terminal pyrin
domain (PYD) and a C-terminal caspase recruitment domain
(CARD) (Franklin et al., 2018). Homotypic intramolecular PYD-
PYD interactions initiate formation of a helical filament, which
allows intermolecular CARD-CARD interactions with the CARD
domain of pro-caspase-1, causing its activation to form mature
caspase-1 (Fernandes-Alnemri et al., 2007). Moreover, it has
been demonstrated previously that ASC accumulates in
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cell-free supernatants of inflammasome-activatedmacrophages
and build up ASC aggregates called ASC specks. Extracellular
ASC specks have the ability to recruit and activate pro-cas-
pase-1 and pro-IL-1b in cell cytosol or cell-free supernatant,
further referred to as ‘‘prion-like’’ activities of ASC (Franklin
et al., 2014). In Alzheimer’s pathology, rapidly after being
released, Ab1–42 binds ASC specks and accelerates its oligomer-
ization, indicating cross-seeding activity of ASC in Ab
aggregation (Venegas et al., 2017).
Here we aimed to investigate the effects of ASC-Ab compos-
ites on NLRP3 inflammasome activation in primary mouse
microglia. We show that exogenous ASC induces ASC-depen-
dent mechanisms in otherwise ASC-deficient microglia.
Moreover, ASC-Ab composites amplified NLRP3 inflammasome
activation in comparison with ASC only or Ab, resulting in pyrop-
totic cell death. In addition, we show that Ab clearance by micro-
glia is impaired in the presence of extracellular ASC aggregates,
suggesting a possible mechanism involved in Ab deposition in
AD. Taken together, our findings indicate that Ab clustering
around ASC fibrils boosts its toxicity in microglia.
RESULTS
Ab monomers have been shown to associate and cluster onto
ASC specks in the extracellular space (Venegas et al., 2017).
To reproduce previous findings in our experimental setup, we
co-incubated ASC with an about 3-fold molar excess of Ab in
serum-free medium or buffer (Figure 1A). Binding of both
proteins was confirmed by transmission electron microscopy
(TEM) (Figures 1B–1D) and co-immunoprecipitation (coIP)
(Figure 1E).
In electron microscopy (EM), ASC was seen to arrange into
long, slightly twisted helical filaments showing a uniform surface
(Figure 1B). In contrast, Ab formed oligomeric complexes
(Figure 1C) that were found in close association with ASC fibrils
when co-incubated (Figure 1D). These data were confirmed by
coIP analysis using anti-ASC and anti-Ab specific antibodies,
respectively, indicating interaction of ASC and Ab in a cell-free
environment (Figure 1E).
To analyze the effect of these ASC-Ab composites on cell
survival in primary microglia, lipopolysaccharide (LPS)-primed
cells were treated with ASC1.75mM, Ab5mM, or ASC1.75mM-Ab5mM
composites for 12 h and 24 h, respectively (Figure 1F). Release
of lactate dehydrogenase (LDH) in response to ASC-Ab treat-
ment was used as an indicator of cell death (Giordano et al.,
2011). Irrespective of LPS priming, microglia exposed to ASC-Ab
composites showed a significant increase in LDH release
compared with ASC or Ab alone (Figure 1G). Interestingly, the
metabolic activity in microglia treated with ASC-Ab composites
did not change within 12 h but was significantly reduced after
24 h compared with ASC- or Ab-treated cells (Figure 1H).
ASC-Ab Composites Activate the NLRP3 Inflammasome
and Induce Pyroptotic Cell Death in Microglia
To study whether the observed cell death of microglia in
response to ASC-Ab composite treatment originates from
pyroptosis, we correlated NLRP3 inflammasome activation. As
expected, LPS treatment of microglia induced priming of the
inflammasome, as shown by an increased expression level of
the receptor protein NLRP3 in the cell lysate, whereas the levels
of pro-caspase-1 remained unaltered (Figures 2A, 2B, and 2D).
Interestingly, caspase-1 cleavage was significantly increased
in response to ASC-Ab composite treatment in both cell lysates
(Figures 2C and 2D) and supernatants (Figures 2K and 2L). More-
over, significantly higher levels of ASC were detected in cell
lysates of the composite-treated group in comparison with
ASC only, occurring with all detected ASC aggregates:
ASC-mCherry, ASC dimers, and ASC monomers (Figures 2E–
2H). In contrast, microglia supernatants showed higher levels
of ASC monomer after composite treatment (Figures 2J and
2L), whereas dimers stayed constant (Figures 2I and 2L).
To discriminate between cell-derived and recombinant human
ASC used for cell treatment, a mouse-specific anti-ASC anti-
body was applied to visualize ASC aggregation and speck
release into the extracellular environment (Figure S1). In addition
to ASC speck formation, we observed morphological changes in
microglia in the course of ASC speck formation. ASC-expressing
microglia displayed a ramified shape, whereas microglia
retracted their processes, resulting in a more activated pheno-
type during ASC speck formation. ASC speck-releasing cells
were further found to undergo transformation, resulting in a high-
ly activated phenotype, potentially indicating pyroptosis.
Tomonitor the release of IL-1b into the extracellular space as a
consequence of ASC speck formation and subsequent caspase-
1maturation, we performed ELISA experiments after 12 and 24 h
of treatment (Figure 3A). ASC only as well as ASC-Ab compos-
ites led to a significant increase in IL-1b release after both time
points compared with Ab alone. Interestingly, ASC-Ab compos-
ites significantly augmented IL-1b levels compared with ASC
only (2.6-fold after 12 h and 1.8-fold after 24 h). The highest
absolute IL-1b levels were determined after 12 h of treatment;
hence, the following experiments were performed using this
time point only.
Besides cleavage of pro-IL1b and pro-IL-18, caspase-1 also
cleaves GSDMD, which subsequently forms GSDMD pores
that facilitate secretion of mature IL-1b into the supernatant
(Rathinamet al., 2019). Tomonitor the effect of ASC-Ab compos-
ites on cleavage of GSDMD, the levels of full-length and amino-
terminal GSDMD (NTD) in response to the respective treatment
were determined by western blotting (Figures 3B–3D). Interest-
ingly, treating the cell with ASC-Ab composites largely induced
GSDMD cleavage in microglia (Figures 3C and 3D), which is in
line with the IL-1b release we detected by ELISA readings
(Figure 3A).
To elucidate the underlying mechanism by which ASC-Ab
composites activate the NLRP3 inflammasome, we tested for
involvement of Toll-like receptors (TLRs) because these recep-
tors have been found to play a key role in neuroinflammation
(Kumar, 2019). To analyze the effect of TLR2, TLR4, and TLR5,
release of IL-1b was determined in LPS-primed microglia
exposed to ASC-Ab composites in the presence or absence of
TLR-neutralizing antibodies (Figure 3E). Here we show that
TLR2 and TLR4 neutralization significantly decreased release
of IL-1b. In contrast, inhibition of TLR5 slightly increased IL-1b
levels in the supernatant. The corresponding immunoglobulin
G (IgG) isotype controls did not have any effect.
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To determine whether release of IL-1b in response to ASC-Ab
composites is NLRP3 dependent, we again co-treated microglia
with ASC-Ab composites and the specific NLRP3 inhibitors
CRID3 (MCC950) and IFM-2384 (Figure 3F). As expected,
co-treatment with both inhibitors led to a significant reduction
in IL-1b release by about 40%. To determine whether IL-1b (Fig-
ure 3F) was processed, we performed an immunoblot analysis of
supernatants (Figure S2E). We found that CRID3 and IFM-2384
treatment decreased the release of mature IL-1b from
microglia but detected continuously high amounts of pro-IL-1b
in the supernatants. In addition, immunoblot analysis consis-
tently detected an additional unconventional precursor form of
pro-IL-1b at around 25 kDa (p25) besides the conventional
31 kDa (p31) form. These data confirm that high amounts of
pro-IL-1b were released and detected by our ELISAs.
IL-1b Release Induced by ASC-Ab Composites Depends
on ASC’s Fibrillation Ability
To determine whether activation of the NLRP3 inflammasome
and the subsequent increase in IL-1b release is dependent on
the fibrillation potential of ASC, we generated an ASC variant
incapable of filament formation. Indeed, TEM revealed that
mutant ASC carrying three mutations within the PYD interface
(K21E, K22E, and K26E) and two mutations within the CARD
domain (D134R and Y187E) lacks filament formation (Figure 3G).
Interestingly, ASC-Ab composites containing mutated ASC
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Figure 1. Ab Clusters around ASC Fibrils, Forming ASC-Ab Composites that Induce Cell Death
(A) Schematic drawing of the ASC-Ab composite-building protocol.
(B–D) EM of ASC fibrils (B), Ab (C), and ASC-Ab composites (D).
(E) coIP of pre-incubated ASC and Ab, confirming binding of ASC to Ab and formation of composites. Left: immunoblot (IB), ASC (AL-177). Center: IB, Ab (82E1).
Right: IB input control.
(F) Schematic drawing of the experimental setup used in this study.
(G and H) LDH release (G) and metabolic activity (H) measurements after 12 and 24 h of treatment with different components.
Data were collected from three independent experiments (n = 3) with three technical replicates per assay (N = 9). All graphs are presented as mean ± SEM and
were analyzed by two-way ANOVA followed by Tukey’s multiple comparisons test. Levels of significance are indicated as follows: *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.0001. Asterisks indicate significance between groups connected by lines; plus symbols indicate significance between ASC-Ab composites
and volume-equal buffer control-treated groups.
Scale bars, 200 nm (B–D).
Cell Reports 30, 3743–3754, March 17, 2020 3745
induced only half of the IL-1b release measured after treating the
cells with non-mutated ASC-Ab composites (Figure 3H).
Exogenous ASC Induces Caspase-1 Cleavage and IL-1b
Release in ASC-Deficient Microglia
ASC is known to possess prion-like activity as it propagates from
a pyroptotic macrophage to another recipient cell while preser-
ving its activity. Moreover, accumulation of extracellular ASC
specks has been shown to induce IL-1b maturation in bone
marrow-derived macrophages (Franklin et al., 2014). To investi-
gate whether similar prion-like activity of ASC can be observed in
microglia, we treated ASC-deficient macrophages and ASC-
deficient primary microglia with exogenously applied recombi-
nant ASC (Figure 4). To mimic a second stimulus for NLRP3
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Figure 2. ASC-Ab Composites Induce Caspase-1 Cleavage to a Greater Extent Than ASC or Ab Alone
(A–C and E–G) IB analysis and quantification of cell lysates of primary WT microglia primed for 3 h with 100 ng/mL LPS and exposed to ASC, Ab, or ASC-Ab
composites for 12 h. Blots of cell lysates of primaryWTmicroglia (D andH) were stained for NLRP3 (A), caspase-1 (B andC), different conformations of ASC (E–G),
and GAPDH.
(I–K) IB analysis using precipitated supernatants (L)were stained for ASC dimers (I), ASC monomers (J), and cleaved caspase-1 subunit p20 (K).
Empty wells and wells containing experimental samples that are not part of this study are not displayed. Vertical lines in blots indicate spliced sections (D, H, and
L). For better reader convenience, the GAPDH signal, which belongs to the same original blot, has been separated in (D) and (H). Data were collected from four (C,
E, I, J, and K) or eight (A, B, F, and G) independent experiments (n = 4 or 8). All graphs are presented as mean ± SEM and were analyzed by one-way ANOVA in
conjunctionwith Tukey’s test (A, B, E–G, and I–K) and Kruskal-Wallis test combinedwith a Dunn’s post hoc test (C). Levels of significance are indicated as follows:
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Asterisks indicate significance between groups connected by lines; plus symbols indicate significance between
ASC-Ab composites and volume-equal buffer control-treated groups.
See also Figure S1.
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inflammasome activation, adenosine triphosphate (ATP) was
used as a positive control (Karmakar et al., 2016). As expected,
ATP induced caspase-1 activation in wild-type (WT) cells (data
not shown) but not in ASC-deficient macrophages (Figures 4A
and 4B). Interestingly, exogenously applied ASC largely induced
caspase-1 activity. In line with our data, we detected the highest
levels of caspase-1 activity in macrophages that were exposed
to ASC-Ab composites (Figure 3B). Using ASC-deficient micro-
glia, we measured significantly increased levels of the auto-pro-
cessed caspase-1 fragment p20 in cell supernatants of cells
treated with ASC and ASC-Ab composites (Figure 4C). Again,
treatment with ASC-Ab composites amplified caspase-1 cleav-
age by about 2-fold compared with ASC treatment alone.
Most importantly, exogenously applied ASC induced IL-1b
release in ASC-deficient microglia in a dose- and time-depen-
dent manner (Figure 4D). After 12 h, ASC-Ab composites
elevated IL-1b release nearly 2-fold compared with ASC only.
However, there was no significant difference remaining after
24 h (Figure 4E). When comparing the total extent of IL-1b
measured in ASC-deficient versus WT microglia, is noticeable
that the tendencies of differently treated groups are similar in
both genotypes, although total IL-1b levels are reduced to
approximately 10% in ASC-deficient cells (Figure 4F).
As expected, cell lysates of ASC-deficient microglia exposed
to exogenous ASC showed high total ASC levels (Figures 4G
and 4H). Interestingly, microglia treated with ASC-Ab com-
posites contained significantly more ASC compared with
ASC-only-treated cells.
Next we aimed to investigate whether exogenously applied
ASC, when taken up by ASC-deficient cells, still possesses the
ability to form intracellular ASC specks. Indeed, exposure of
macrophages to ASC increased the number of ASC-positive
cells, which was further enhanced in the ASC-Ab composite-
treated group (Figure 4I). Moreover, by visualization of
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(A) IL-1b levels in conditioned medium of primary microglia after 12 and 24 h of exposure to ASC, Ab, or ASC-Ab composites (n = 3 independent experiments with
triplicate treatments for all conditions).
(B–D) IB analysis and quantification of full-length Gasdermin D (GSDMD; n = 3; B and D) and cleaved NTD (n = 4; C and D). Empty wells and wells containing
experimental samples, which are not part of this study are not displayed. Vertical lines in blots indicate spliced sections (D).
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internalized ASC, we saw that speck formation was further
amplified when cells were treated with ASC-Ab composites (Fig-
ure 4 I, bottom panel).
The interaction of ASC and Ab in cell lysates of ASC-deficient
microglia was still preserved, as shown in coIP experiments (Fig-
ures 4J and 4K). Interestingly, higher quantities of ASC dimers
than ASC monomers were detected in lysates of cells treated
with ASC-Ab composites (Figure 4J).
ASC Binding Exacerbates Uptake of Ab and Decelerates
Its Degradation
Microglia play an outstanding role in amyloid clearance in the
healthy brain but also during AD progression (Baik et al., 2016;
Cho et al., 2014). Thus, we analyzed the potential effect of
ASC-Ab binding on phagocytic clearance of Ab by primary
microglia. To quantify the engulfment of Ab, we treated microglia
either with fluorescein (FAM)-labeled Ab or ASC-FAM-Ab com-
posites and assessed the uptake of Ab using fluorescence-acti-
vated cell sorting (FACS) analysis (Figure S2A). Interestingly, in
the presence of ASC-Ab composites, uptake of Ab was
decreased by about 35%after 1 h comparedwith primarymicro-
glia treated with Ab only (Figures 5A–5C).
In addition to phagocytic uptake, we determined the degrada-
tion capacity of microglia to prove an imbalance in uptake and
degradation. We found that microglia constantly degrade Ab in
a time-dependent manner with a degradation rate of about
20%–25% per hour (Figures 5D and 5E). In contrast, when
microglia were exposed to ASC-FAM-Ab composites, uptake
was largely diminished, and degradation was fully blocked (Fig-
ures 5D and 5E). We confirmed these findings using immunoblot
analysis of cell lysates collected after an allowed degradation
time of 12 h (Figure S2B).
A common factor implicated in a number of cellular processes,
including phagocytosis, proliferation, survival, and regulation of
inflammatory cytokine production, is the receptor TREM2 (Ulrich
and Holtzman, 2016). Consequently, we checked for changes in
TREM2 expression levels by western blot (Figures S2C and
S2D). Interestingly, TREM2 expression was decreased in cells
treatedwith ASC-Ab, indicative of amodulatory effect of ASC-Ab
composites on TREM2 activity. Our data indicate an ASC-Ab-in-
duced imbalance between uptake and degradation, resulting
in deposition of cytotoxic protein accumulation intra- and
extracellularly.
DISCUSSION
The link between Ab deposition and microglial dysfunction has
already been studied extensively (Cai et al., 2014; Sarlus and
Heneka, 2017). Unravelling the underlying pathway, we identified
ASC as a key player (Venegas et al., 2017). Our previous study
found expression of ASC to be increased in an Alzheimer’s
disease mouse model compared with a WT control. Moreover,
ASC was shown to rapidly interact with pathogenic Ab1–42 extra-
cellularly, suggested to underlie microglial dysfunction. Data
showing a direct connection between ASC-Ab composites lead-
ing to microglial dysfunction are still pending; hence, we aimed
to unravel the resulting cellular effects on microglia exposed to
Ab-ASC composites. Indeed, our present study revealed severe
toxicity emanating from ASC-Ab composites compared ASC
only or Ab. Microglia exposed to ASC-Ab subsequently under-
went cell death, displaying increased LDH release (Figure 1G)
and reduced metabolic activity (Figure 1H). In addition, compos-
ite-treated microglia showed ASC speckling (Figure S1),
caspase-1 cleavage (Figures 2C and 2D) and release of its active
fraction (Figures 2K and 2L), pro-inflammatory cytokine matura-
tion (Figure 3A), as well as highly elevated levels of the pore-
forming NTD (Figures 3C and 3D). Thus, we considered the
observed cell death to be pyroptotic. Caspase-1 activity has
been shown to accelerate IL-1b secretion via rapid GSDMD-
dependent pathways (Monteleone et al., 2018). This mechanism
could possibly also underlie the pyroptotic cell fate detected
here.
To confirm NLRP3 dependency of the observed IL-1b release,
we used different modulators to inhibit the NLRP3-initiated ASC
assembly. The resulting total IL-1b levels were reduced by
approximately 40% (Figure 3F), possibly because of decreased
cleavage and impaired release of its mature form (Figure S2E),
also considering further ASC-dependent inflammasomes such
as the AIM or NLRC4 inflammasome (Freeman et al., 2017) to
mediate generation of the remaining IL-1b levels.
Mutagenesis studies showed that clustering of ASCPYD fila-
ments and their condensation into ASC specks is mediated by
the ASCCARD exposed to the surface of the ASCPYD-initiated fila-
ment (Hoss et al., 2017). Furthermore, filament formation served
as an amplification mechanism in inflammasome signaling,
resulting in cytokine maturation (Dick et al., 2016). By mutating
D134 and Y187 within the ASCCARD domain, filament formation
Figure 4. Exogenous ASC Can Replace Endogenous ASC in ASC-Deficient Cells and Induce ASC-Dependent Signaling Pathways
(A and B) Immunocytochemical detection (A) and quantification (B) of caspase-1 activity in ASC-deficient macrophages treated with or without exogenous ASC.
(C) The caspase-1 subunit p20 was detected by IB analysis in precipitated supernatants from ASC-deficient microglia.
(D–F) IL-1b levels in conditioned medium of ASC-deficient primary microglia after exposure to different concentrations of exogenous ASC: c1 = 0.22 mM, c2 =
0.66 mM, c3 = 1.75 mM (D); IL-1b levels in conditionedmedium of ASC-deficient primary microglia treated with ASC, Ab, or ASC-Ab composites for 12 and 24 h (E);
and IL-1b levels in conditioned medium of primary WT microglia and ASC-deficient microglia treated with ASC-Ab composites for 12 h (F).
(G and H) IB analysis and quantification (G) of ASC monomers, dimers, and ASC-mCherry in ASC-deficient microglia cell lysates (H) (n = 4).
(I) Immunostaining of ASC-deficient macrophages treated with exogenous ASC and stained for ASC internalization and ASC speck formation after ASC-Ab
composites treatment (arrowheads).
(J and K) CoIP of ASC and Ab in ASC-deficient microglia cell lysates. IP: ASC. IB: ASC (AL-177) (J), IB: Ab (82E1) and input controls (K). Empty wells and wells
containing a lysate control negative for both proteins are not displayed. Vertical lines in blots indicate spliced sections.
Data were collected from three independent experiments (n = 3) with three technical replicates per assay (N = 9) (D–F). All graphs are presented as mean ± SEM
and were analyzed by two-way ANOVA (D and E), one-way ANOVA in conjunction with Tukey’s test (B, C, and G), or unpaired t test (F). Levels of significance are
indicated as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Asterisks indicate significance between groups connected by lines; plus symbols indicate
significance between ASC-Ab composites and volume-equal buffer control-treated groups. Images were taken at 403magnification. Scale bars, 10 mm (A and I).
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of the CARD domain only is almost completely disrupted (Li et al.,
2018). Particular mutations of the type I interface mediating PYD-
PYD interactions, such as K21Q, K21E/K22E, and K26E, also
abolish formation of the ASCPYD filament (Lu et al., 2014).
Recently, we showed that full-length human ASC carrying three
K-to-Amutationswithin the abovementioned PYD-PYD interface
(K21A, K22A, and K26A) does not cross-seed Ab1–40 aggregation
(Venegas et al., 2017). Using an ASC variant deficient in PYD as
well as CARD-mediated filament formation (K21E, K22E, K26E,
D134 R, and Y187E), release of proinflammatory cytokines
decreased tremendously, suggesting that the filamentary struc-
ture of ASC is mandatory for NLRP3 inflammasome activation
in response to ASC-Ab composites (Figures 3G and 3H).
Here we observed that exogenous ASC induces speck forma-
tion of cell-intrinsic ASC in WT microglia (Figure S1) and itself
formed speck-like aggregates in the cytosol of ASC-deficient
cells (Figure 4I). These findings underline the importance of
ASC aggregation in inducing the NLRP3 inflammasome pathway
(Latz et al., 2013; Stutz et al., 2013). ASC specks have been iden-
tified previously as an endogenous danger signal because injec-
tion of ASC specks caused acute inflammatory reactions in WT
mice (Franklin et al., 2014). In vitro, ASC specks were shown to
accumulated in the extracellular space but still retained the abil-
ity to mature pro-IL-1b. Moreover, it was shown that phagocy-
tosed ASC specks still induced lysosomal damage and IL-1b
production in macrophages.
Activation of the NLRP3 inflammasome by ASC-Ab compos-
ites is thought to be transferred via a still unknown mediator.
Because the expression of multiple TLRs on the microglia
surface increases with the presence of pathogens or other pro-
inflammatory stimuli (Olson and Miller, 2004), we examined the
effect of TLRs. Inhibiting TLR2 and TLR4 significantly decreased
release of IL-1b in response to ASC-Ab treatment (Figure 3E),
supporting the commonly accepted knowledge of Ab being a
target of both cell surface receptors (Letiembre et al., 2009)
and inducing NLRP3 inflammasome activation (Liu et al., 2012;
Walter et al., 2007).
It is speculated that, besides the interaction of Ab with TLR2
and TLR4, multiple cell surface receptors could also be targeted,
including CD36 and TLR6 (Doens and Ferna´ndez, 2014; Sheedy
et al., 2013; Stewart et al., 2010). Ab clustering around the ASC
fibril might enable Ab to interact with various cell surface recep-
tors simultaneously, presumably boosting intracellular inflam-
matory cascade activation, revealing the toxicity of ASC-Ab
composites.
It has been shown recently that the soluble TLR5 Fc-fragment
binds to oligomeric as well as fibrillar Ab with high affinity and
blocks its toxicity. Moreover, Ab has been shown to modulate
flagellin-mediated activation but does not by itself activate
TLR5 signaling (Chakrabarty et al., 2018). Supporting the
hypothesis of a protective role of TLR5, we showed that an
increase in IL-1b levels in response to ASC-Ab exposure is deter-
mined only in presence of a specific TLR5 inhibitor (Figure 3E).
Here, we present evidence that exogenous ASC has the abil-
ity to induce caspase-1 cleavage (Figures 4A–4C) and IL-1b
maturation (Figures 4D and 4E) not only in peripheral macro-
phages but also in microglia, using an ASC-deficient genotype.
ASC-Ab composites induced higher p20 and IL-1b levels than
ASC alone, showing the same tendencies as in the WT but
reaching lower absolute values (Figure 4F), suggesting that
cell-intrinsic ASC speck formation, which is also induced by
ASC-Ab composites (Figure S1), plays an important role in
exogenous ASC-Ab toxicity. Indeed, we detected higher levels
of ASC in microglia lysates after ASC-Ab composite treatment
compared with ASC-only exposure, assuming that the
increased uptake of ASC is composite mediated, which, in
turn, leads to increased NLRP3 inflammasome activity (Figures
4G and 4H).
Of note, a stable interaction of ASC and Ab is assumed
because both proteins stay bound within the cell lysates (Figures
4J and 4K). Thus, it is hypothesized that Ab stabilizes the ASC
fibril intracellularly and possibly extends its time of availability
and/or accelerates the pro-inflammatory cascade.
As described previously, missense variants in the TREM2
receptor are associated with a 2- to 4-fold increased risk of
developing AD (Guerreiro et al., 2013; Jonsson et al., 2013).
Moreover, it has been shown that exogenous expression of
TREM2 in Chinese hamster ovary (CHO) or HEK293 cells
increases phagocytic activity (Kleinberger et al., 2014; N’Diaye
et al., 2009). Furthermore, TREM2 overexpression promotes
clearance of Ab1–42 by BV-2 cells and restored cell viability
from Ab-mediated neuroinflammation by downregulating TLRs
(Long et al., 2019). However, inflammatory stimuli decrease
TREM2 expression in vitro but increase TREM2 expression
in vivo (Jay et al., 2017).
Our findings revealed increased pro-inflammatory cytokine
levels (Figure 3A) in a TLR2-, TLR4-, and TLR5-dependent
manner (Figure 3E). Moreover, a decrease in phagocytic activity
(Figures 5A–5C) as well as a reduction in TREM2 expression
(Figures S2C and 2D) in response to exposure of ASC-Ab
Figure 5. Ab Clearance by Microglia Is Affected When Bound to ASC
(A) Representative FACS graphics demonstrating the engulfment of Ab by microglia upon treatment with Ab only or ASC-Ab composites for 15, 30, and 60 min.
(B) Quantification of microglia engulfing Ab over time.
(C) Phagocytic index of microglia engulfing Ab over time.
(D and E) Quantification and comparison of relative Ab degradation byWTmicroglia over 1, 2, 3, and 4 h in the presence or absence of ASC, measured after 1 h of
Ab phagocytosis.
(D) Quantification of Ab-positive microglia over time.
(E) Fluorescence index of microglia degrading Ab over time.
Data were collected from three independent experiments (n = 3) with two technical replicates per assay (N = 6). All graphs are presented asmean ±SEMandwere
analyzed by paired t test for phagocytic cells and index (B and C) as well as two-way ANOVA followed by Tukey’s multiple comparisons test for degradation
analysis (D and E) and unpaired t test for area under the curve (AUC; percentage of Ab-treated primary microglia [PMG]; B–E). Levels of significance are indicated
as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
See also Figure S2.
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composites suggests a connection between these findings. We
could also show that clustering of microglia to ASC fibrils
resulted in impaired Ab uptake (Figures 5A–5C). Further studies
might consider the effect of TREM1 and TREM2 on ASC-Ab
phagocytosis because there is growing evidence that their over-
expression increases Ab clearance by microglia (Jiang et al.,
2016; Xiang et al., 2016). In addition, microglia exposed to
ASC-Ab composites lost their ability to degrade Ab compared
with microglia exposed to Ab only (Figures 5D and 5E;
Figure S2B). Aggregate size as well as the interaction of ASC
and Ab itself might underlie the altered phagocytosis. Altogether,
these findings reveal a possible mechanism involved in AD
progression because Ab plaque clearance bymicroglia is essen-
tially important in the disease context (Hansen et al., 2018; Sarlus
and Heneka, 2017).
Conclusions
Taken together, ASC contributes prion-like activities in microglia
as in macrophages. Cells undergoing pyroptosis set free fully
functional ASC that can be built into the NLRP3 inflammasome
of the recipient cell. Even ASC-deficient cells were shown to
induce caspase-1 cleavage and pro-inflammatory cytokine
maturation mediated by exogenous ASC. In WT microglia, ASC
induced cell-intrinsic ASC speck formation and release. Further-
more, exogenous ASC itself also formed speck-like aggregates
inside the cell. Clustering of Ab onto ASC fibrils led to multiple
cellular responses, such as an increase in caspase-1 activation,
IL-1b maturation, and cleavage of GSDMD. Moreover, ASC
specks were found to be formed faster, and ASC was taken up
in higher quantities. ASC and Ab remained bound in the cell
lysates, assuming Ab to stabilize the ASC fibril and thereby
Figure 6. ASC-Ab Binding Induces a Vicious Cycle in Microglia
The schematic was created with BioRender (https://biorender.com). Ab induces microglia activation via multiple cell surface receptors. Here we display TLRs as
an example. Under healthy conditions, microglia activation leads to engulfment and clearance of Ab. During microglia activation, NLRP3 inflammasome
components, such as the adaptor protein ASC and the pro-inflammatory cytokines IL-1b and IL-18, are released to the extracellular space. There, Ab clusters
around ASC fibrils, resulting in ASC-Ab composite formation. ASC-Ab composites themselves boost NLRP3 inflammasome activation in the surrounding
microglia, reducing microglia Ab clearance ability and resulting in pyroptotic cell death. During pyroptosis, vast quantities of ASC are set free, starting the vicious
cycle of ASC-Ab composites all over. In the AD brain, this might be a reason for increased Ab deposition.
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boosting its toxicity. Thus, cells exposed to ASC-Ab subse-
quently underwent pyroptosis, setting free ASC and leading to
activation of the surrounding cells, inducing a vicious circle
(Figure 6). Furthermore, ASC-Ab binding was shown to prevent
Ab clearance by microglia in vitro, which might play a role in
AD progression in vivo.
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KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti-Asc (AL177) antibody AdipoGen Cat# AG-25B-0006; RRID: AB_2490440
Rat anti-Caspase-1 (clone 4B4) antibody Genentech Cat# CASP-1(mu):4175
Rabbit anti-GAPDH antibody Sigma-Aldrich Cat# G9545; RRID: AB_796208
Rabbit anti-GSDMD antibody [EPR19828] Abcam Cat# ab209845; RRID: AB_2783550
Mouse anti-NLRP3/NALP3 (Cryo-2) antibody AdipoGen Cat# AG-20B-0014-C100; RRID: AB_2490202
APC rat anti-mouse/human CD11b antibody Bio Legend Cat# 101212; RRID: AB_312795
Mouse specific rabbit anti-ASC/TMS1 (D2W8U)
antibody
Cell Signaling Technology Cat# 67824; RRID: AB_2799736
Rabbit anti-b-actin antibody Cell Signaling Technology Cat# 4967; RRID: AB_330288
Goat anti-rabbit-AlexaFluor488 (H+L) antibody Thermo Fisher Scientific Cat# A-11008, RRID: AB_143165
Goat anti-rat-AlexaFluor594 antibody Invitrogen Cat# A11007; RRID: AB_141374
Rabbit anti-IL-1b antibody GeneTex Cat# GTX74034; RRID: AB_378141
IRDye 680LT donkey anti-mouse IgG (H+L) antibody LI-COR Biotechnology Cat# 926-68022; RRID: AB_10715072
IRDye 800CW goat anti-rat IgG (H+L) antibody LI-COR Biotechnology Cat# 926-32219; RRID: AB_1850025
Mouse anti-Ab (82E1) antibody IBL America Cat# 10323; RRID: AB_1630806
Mouse IgG Isotype Control antibody Thermo Fisher Scientific Cat# 10400C; RRID: AB_2532980
Mouse TLR2 neutralizing antibody (C9A12) InvivoGen Cat# mabg-mtlr2; RRID: AB_11125339
Mouse TLR5 neutralizing antibody (Q23D11) InvivoGen Cat# mabg-mtlr5; RRID: AB_11124926
Rat anti-mouse CD11b antibody Serotec by Bio-Rad Cat# MCA711; RRID: AB_321292
Rat IgG Isotype Control antibody Thermo Fisher Scientific Cat# 10700; RRID: AB_2610661
TLR4/MD-2 Complex Monoclonal Antibody (MTS510) Invitrogen Cat# 14-9924-82; RRID: AB_468617
Goat anti-Trem2 antibody GeneTex Cat# GTX47596; RRID: AB_10618011
Chemicals, Peptides, and Recombinant Proteins
Ampicillin sodium salt Carl Roth Cat# K029.1
4’,6-Diamidino-20-phenylindol-dihydrochloride (DAPI) Thermo Fisher Scientific Cat# 62247
Adenosine 50-triphosphate disodium salt hydrate Sigma-Aldrich Cat# A2383
Amyloid b-Protein (1-42) (HFIP-treated) Bachem AG Cat# 4090148
Bovine Serum Albumin - Fraction V Rockland Immunochemicals, Inc. Cat# BSA-1000
FAM-labeled Amyloid b Peptide Specialty Laboratories
GmbH (PSL)
ID# CEM112812FL
Fetal Bovine Serum LIFE Technologies Cat# 10270106
Guanidine hydrochloride Carl Roth Cat# 6069.3
HisTrapTM FF crude GE Healthcare Cat# 17528601
IFM-2384 IFM Therapeutics gift from IFM
Lipopolysaccharide from Escherichia coli K12 InvivoGen Cat# tlrl-eklps
MCC950 (CRID3) InvivoGen Cat# inh-mcc
N2-Supplement GIBCO by Thermo Fisher Scientific Cat# 17502048
NdeI New England Biolabs Cat# R0111S
Normal Goat Serum Abcam Cat# ab7481
NuPAGE 4-12% Bis-Tris gel Invitrogen Cat# NP0323BOX
NuPAGE MES SDS Running Buffer (20X) Thermo Fisher Scientific Cat# NP0002
Orange G Carl Roth Cat# 0318.2
Paraformaldehyde Sigma-Aldrich Cat# P6148
pET23a Novagen Cat# 69745
(Continued on next page)
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pET23a-ASC-tev-mCherry Venegas et al., 2017 N/A
Poly-L-Lysine Hybridomide Sigma-Aldrich Cat# P1524
Protease/Phosphatase Inhibitor Cocktail (100X) Cell Signaling Technology Cat# 5872
Protein LoBind Tubes Eppendorf 0030108116
Q5 High Fidelity DNA polymerase New England Biolabs Cat# M0491S
SureBeadsTM Protein G Magnetic beads Bio-Rad Laboratories Cat# 1614023
T4 DNA Ligase New England Biolabs Cat# M0202S
Trans-Blot Turbo Mini Nitrocellulose Transfer Packs Bio-Rad Laboratories Cat# 1704158
Critical Commercial Assays
Cytotoxicity Detection Kit (LDH) Roche Cat# 11644793001
FAM-FLICA Caspase-1 Assay Kit ImmunoChemistry Technologies Cat# 98
Mouse IL-1 beta/IL-1F2 DuoSet ELISA R&D Systems Cat# DY401
PierceTM BCA Protein Assay kit Thermo Fischer Scientific Cat# 23225
PierceTM LAL Chromogenic Endotoxin Quantitation Kit Thermo Fischer Scientific Cat# 88282
QIAprep Spin Miniprep Kit QIAGEN Cat# 27104
QIAquick Gel Extraction Kit QIAGEN Cat# 28704
QIAquick PCR Purification Kit QIAGEN Cat# 28104
XTT Cell Viability Kit Cell Signaling Technology Cat# 9095
Experimental Models
NCTC clone 929 (L929 cells), strain: C3H/An ATCC Cat# CCL-1; RRID: CVCL_0462
Primary microglia isolated from C57BL/6 mice Charles River Laboratories RRID: IMSR_JAX:000664
Primary microglia isolated from C57BL/6 ASC/mice Millenium Pharmaceuticals N/A
E. coli BL21 (DE3), genotype: F– ompT hsdSB
(rB–, mB–) gal dcm (DE3)
Merck Cat#69450.
Software and Algorithms
FACSDIVA software Becton Dickinson N/A
Fiji ImageJ Wayne Rusband v2.0.0-rc-69/1.52n
FlowJo FlowJo, LLC v3.05470
Graph Pad Prism GraphPad Software Inc. v7.0e
Image Studio LI-COR Biosciences v5.2
NIS-Elements Nikon v4.0
Other
Avanti J265 XP centrifuge Beckmann Coulter equipment
A¨KTAprime plus FPLC system GE Healthcare equipment
BD FACSCantoTM II BD Biosciences equipment
Eppendorf BioPhotometer D30 Eppendorf equipment
Infinite M200 Pro TECAN equipment
JA-25.50 Fixed-Angle Rotor Beckmann Coulter equipment
JEOL JEM-2200FS Field Emission Transmission
Electron Microscope equipped with a CMOS-Camera
JEOL GmbH equipment
JLA-8.1000 Fixed-Angle Rotor Beckmann Coulter equipment
JULABO 5 water bath JULABO GmbH equipment
Lab 850 pH-Meter Schott Instruments equipment
Multitron pro Infors HT equipment
NanoDrop 2000c Spectrophotometer Thermo Scientific equipment
Nikon Eclipse Ti Fluorescence Microscope Nikon equipment
ODYSSEY CLx Imaging System LI-COR Biotechnology equipment
Optima TLX ultracentrifuge Beckmann Coulter equipment
TLA-120.2 Fixed-Angle Rotor Beckmann Coulter equipment
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LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Michael T.
Heneka (michael.heneka@ukbonn.de).
This study did not generate new unique reagents.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Animals
All animals used for cell isolation were treated according to the legal and ethical requirements of the University of Bonn – Medical
Center (Germany). Mouse breeding and husbandry were approved by the veterinary office (Bonn, Germany) according to theGerman
animal welfare act. The procedures complied with the guidelines of animal welfare as laid down by the German Research Council
(DFG). For this study brains of P0–P2,mixed gender C57BL/6WT (purchased fromCharles River Laboratories Inc.) and ASC-deficient
(purchased from Millenium Pharmaceuticals) mice were used.
METHOD DETAILS
Cell Culture
Primary microglia were isolated according to the method of Giulian and Baker (1986). After removing the meninges, cells were
separated using mechanical shearing and 0,25% trypsin (GIBCO by lifeTechnologiesTM). Subsequently, cells were transferred into
Poly-L-Lysine (PLL) (Sigma-Aldrich) coated T75 culture flasks (Greiner Bio-One) and cultured under standard conditions at 37C
and 5% CO2 (1-2 brains per flask). On the next day, flasks were washed three times with Dulbecco’s Phosphate Buffered Saline
(DPBS) (GIBCO) and cultured for an additional 7-10 days in Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) containing
10%heat-inactivated Fetal Bovine Serum (iFBS) (GIBCO), 1%Penicillin/Streptomycin (P/S) (GIBCO) and 1mL of filtered L929 cell su-
pernatant as a source for growth factors. Cultures were regularly checked for loosely attached mature microglia. Finally, microglia
were shaken off from the astrocyte monolayer after 7-10 days followed by two more shake off cycles every second to third day.
Preparation of Recombinant ASC
Full-length human ASC, followed by a TEV protease cleavage site and mCherry, was cloned in NdeI/XhoI sites of a pET-23a expres-
sion vector providing aC-terminal hexa-histidine tag. This construct was transformed and expressed in E. coli cells (strain BL21(DE3))
by growing the culture at 37C to an OD600 of 0.8 and induced with 0.1 mM isopropyl b-D-1-thiogalactopyranoside for 4 h at 37C.
Cells were collected by centrifugation and lysed by sonication in a lysis buffer A containing 20 mM Tris (pH 8.0), 500 mM NaCl and
5mM imidazole. Cell lysates were then centrifuged at 20,000 x g for 30min and the pellet was dissolved in buffer A supplementedwith
2 M Gdn-HCl for 1 h at 4C. Subsequently, the suspension was again centrifuged at 20,000 x g for 30 min and the supernatant was
dialysed against buffer A O/N at 4C, while continuously stirring. On the next day, the sample was centrifuged as described above
and the supernatant was administered to a pre-equilibrated HisTrapTM column using an A¨kta Prime FPLC system (GE Healthcare).
The column was washed with 10 column volumes of lysis buffer A and the protein was eluted in the same buffer supplemented with
200mM imidazole. Subsequently, the purified protein was dialysed against buffer B containing 20mMTris (pH 8.0) and 300mMNaCl
O/N at 4C, while continuously stirring. Finally, endotoxin concentration was controlled using the PierceTM LAL Chromogenic Endo-
toxin Quantification Kit (Thermo Fischer Scientific) according to the manufacturers protocol. In order to separate soluble ASCmono-
mers from insoluble aggregated forms the solution was centrifuged for 30 min at 100.000 x g in a TLA-120.2 rotor or equivalent in a
Beckman Optima TLX benchtop ultracentrifuge. To induce fibrillation the ASC-containing solution was transformed to LoBind Tubes
(Eppendorf) and incubated for 1 h at 37C. The final concentration of ASCwas quantified byNanoDrop using the extinction coefficient
ε = 61.31. ASC fibrils were kept at 4C for no longer than 3 weeks.
In addition to WT ASC, a mutated ASCwas generated, carrying mutations in the PYD-PYD assembly interface (K21E, K22E, K26E)
(Lu et al., 2014) and in the caspase-recruitment domain (CARD) (D134R, Y187E) (Li et al., 2018). Mutated ASC was generated
following the same procedure as WT ASC.
Preparation of Amyloid b
Amyloid b (Ab) protein (1-42) was ordered 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP)-treated (Bachem AG), dissolved in sterile
Dulbecco’s phosphate buffered saline (DPBS) (GIBCO) and stored at 80C (Go¨tz et al., 2001). As a working concentration, 5 mM
was used for cytotoxicity and cell viability assays, immunoblotting and ELISA.
Continued
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Vibra-Cell ultrasonic liquid processor Sonics equipment
Cell Reports 30, 3743–3754.e1–e6, March 17, 2020 e3
For phagocytosis and degradation assays as well as for immunocytochemistry (ICC) FAM-labeled Ab1-42 (Peptide Specialty
Laboratories GmbH) was solved in 40 mM NaOH at 4 mg/ml, diluted in Tris-HCL (pH 7.4) to 1 mg/mL (221 mM), incubated for
1 day at 37C and finally stored at 80C.
Building ASC-Ab Composites
Fibrillary ASC (1.75 mM) and Ab1-42 monomers (5 mM) were incubated in serum-free DMEM containing 1% P/S and 1% N-2 supple-
ment in LoBind Tubes (Eppendorf) at 37C,O/N. The same culture procedurewas applied to single protein treatments and the volume
equal buffer controls.
Protein Determination
To determine protein concentrations of cell lysates, a bicinchoninic acid assay was performed using PierceTM BCA Protein assay kit
(Thermo Fischer Scientific) according to the manufacturer’s protocol.
Co-Immunoprecipitation (Co-IP)
For Co-IP experiments, 50 mL of SureBeadsTM Protein G Magnetic beads (Bio-Rad Laboratories) were magnetized and washed with
PBS (Dulbecco) supplementedwith 0.1%Tween-20 (PBST) for three times. Thereafter, beadswere incubatedwith either 2mgof rabbit
anti-ASC (cloneAL177, AdipoGen) or 0.3 mgofmouse anti-Ab (82E1) (IBL America) in a total volumeof 200 mLPBST for 10min at RT on
a rotator. After that, beads were magnetized and washed three times with PBST. The antigen-containing solutions were added and
incubated again for 1 h at RT on a rotator. For ASC-Ab Co-IP’s 1.75 mMASC and 5 mMAbwere pre-incubated in serum-free medium
O/N before co-culturing themwith beads. For studying the intracellular bonding state of ASC and Ab, ASC-deficient microglia lysates
containing 35 mg total protein were added to a total volume of 200 mL PBST. Cell seeding, treatments and lysate collection were
performed as explained in the ‘‘Immunoblotting (IB)’’ section. Antibody controls were incubated with 200 mL PBST in parallel.
Subsequently, beads were magnetized and washed three times with PBST. To separate the antibody-bead binding, beads were
resuspended in 40 mL loading buffer (106 mM Tris-HCL, 141 mM Tris base, 2% LDS, 10% glycerol, 0.51 mM EDTA (pH 8.5),
360 mM 1,4-Dithiothreit (DTT), and 5 mg/mL Orange G) and heated at 70C, 600 rpm for 10 min. For immunoblotting, every vial
was divided equally into two wells. Immunoblotting was then performed as described below.
Electron Microscopy
Fibrillary ASC (1.75 mM) and Ab1-42 monomers (5 mM) were pre-incubated in buffer B (see above) O/N at 37
C. For negative staining
electronmicroscopy, 4 mL of the protein sample was applied to a glow discharged copper grid and incubated for 1min. Sampleswere
washed three times bydipping the sample side into a dropof protein buffer before fluidswere removedby the aid of a filter paper. Than
samples were negatively stained by dipping them twice into a drop of 2% uranyl acetate following a 30 s incubation step and finally
removing residual fluids using a filter paper. Afterward, the EM grid was air-dried and immediately processed. Samples were imaged
using aJEOLJEM-2200FS200kVTransmissionElectronMicroscope (TEM) equippedwith aCMOS-Camera (TemCam-F416, TVIPS).
Cytotoxicity and Cell Viability Assays
For viability and cytotoxicity experiments, primary microglia were seeded at a density of 7.5 3 104 cells/well in 150 mL DMEM
containing 1% P/S and 1% N-2 supplement (GIBCO) in a 96-well plate and allowed to attach O/N. After pre-simulation with
100 ng/mL lipopolysaccharide (LPS) (InvivoGen) for 3 h, wells were washed once with DMEM and treated with either 1.75 mM
ASC, 5 mM Ab, ASC-Ab composites (containing 1.75 mM ASC and 5 mM Ab) or its buffer controls (20 mM Tris (pH 8.0) and
300 mM NaCl (‘‘buffer B’’) for ASC and DPBS for Ab) for 12 and 24 h. Subsequently, LDH release was measured using 50 mL super-
natant and a cytotoxicity detection kit (Roche) according to the manufacturer’s protocol. The reaction was stopped with 1 N HCl and
absorbance was measured at 490 and 680 nm using a microplate reader (Infinite M200; Tecan).
To determine cell viability, the XTT Cell Viability Kit (Cell Signaling Technology) was used according to the manufacturer’s
protocol. In brief, 150 mL phenol red-free DMEM (GIBCO) per well was mixed with 50 mL of XTT Reagent and 1 mL Electron Coupling
Solution and added to the microglia. After 1 h the absorbance was measured at 450 nm with a TECAN microplate reader.
Immunoblotting (IB)
Primarymicroglia were seeded at a density of 1.53 106 cells/well in 2mL serum free DMEM in a 6-well plate. After pre-stimulating the
microglia with 100 ng/mL LPS, cells were treated as mentioned in the ‘‘Cytotoxicity and Cell Viability Assays’’ section above. After
12 h of treatment, supernatants were collected, centrifuged at 15.000 x g for 5 min to remove cell debris, and stored at 20C for
protein precipitation.
For protein precipitation (Scheiblich et al., 2017), 500mLmethanol and 125mL chloroform were added to 500mL supernatant and
vortex vigorously. Supernatants and used solutions were therefor kept on ice continuously. After 5 min centrifugation at 15,000 x g at
4C the upper aqueous phase was removed carefully and again 500 mL ice-cold methanol were added to the remaining liquid.
Samples were then vortexed vigorously and repeatedly centrifuged for 5 min at 13,000 x g at 4C. Supernatants were removed
and pellets were dried for 5 min in a vacuum dryer. The pellets were then resuspended in 10 mL 2 X loading buffer (see above)
and denaturated (see below). Subsequently, samples were subjected to western blot analysis.
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For lysate collection, cells were scraped of the well plate, centrifuged at 15,000 x g for 5 min and pellets were lysed using 1 X
ristocetin-induced platelet agglutination (RIPA) buffer (25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% sodium desoxycholate, 1%
NP-40, and 0.1% SDS) supplemented with 1 X Protease/Phosphatase Inhibitor Cocktail (Cell Signaling Technology). Cell lysates
and precipitated supernatants were denaturated in loading buffer at 95C and 360 rpm for 5 min in a thermo cycler. Samples were
separated on a NuPAGE 4%–12% Bis-Tris Gel (Invitrogen) in NuPAGEMES or MOPS SDS Running Buffer (NP0002) depending on
the size of the respective protein of interest. The Trans-Blot TurboTM Transfer System (Bio-Rad Laboratories) was used to blot the
proteins on a 0.2 mm nitrocellulose membrane (Trans-Blot TurboTM Transfer Pack, Bio-Rad Laboratories). Thereafter, membranes
were blocked with 3% fatty acid-free bovine serum albumin (BSA) (Millipore) in Tris-buffered saline supplemented with Tween-20
(TBST) (10 mM Tris-HCl, 150 mM NaCl, 0.05% Tween-20, pH 8.0) for 1 h at RT, followed by incubation with the primary antibodies
mouse anti-NLRP3 (1:1000, AdipoGen), rat anti-caspase-1 (1:1000, clone 4B4, Genentech), rabbit anti-ASC (1:1000; clone AL177,
AdipoGen), rabbit anti-GSDMD (1:1000, Abcam), goat anti-TREM2 (1:1000, GeneTex), mouse anti-Ab (82E1) (1:1000, IBL America),
rabbit-anti-IL-1b (1:500, GeneTex), rabbit anti-GAPDH (1:1000, Sigma-Aldrich) and rabbit anti-b-actin (1:1000, Cell Signaling Tech-
nology), O/N at 4C, respectively. On the next day,membranes were washed three times in TBST and incubated with the respective
secondary IRDye IgG (H + L) antibodies (1:10 000, LI-COR Biotechnology) for 1 h at RT. Proteins were then visualized with the
Odyssey Fc or CLx Imaging System (LI-COR Biosciences) and quantified using Image Studio (LI-COR Biosciences).
Measurement of Cytokine Secretion
Primary microglia were treated as described above in the ‘‘Cytotoxicity and Cell Viability Assays’’ section. Microglial IL-1b secretion
was measured in cell supernatants using the mouse IL-1b/IL-1F2 DuoSet ELISA (R&D Systems) according to the manufacturer’s
protocols. The reaction was terminated by adding 2 N H2SO4, and the optical density was measured at OD450 with a microplate
reader. To determine cytokine concentrations, values were interpolated into the standard curve by linear regression using GraphPad
Prism 7 (GraphPad Software).
For Toll-like receptor (TLR) neutralization experiments, cells were co-treated with anti-mouse TLR4/MD-2 Complex (clone:
MTS510, Invitrogen), Mab-mTLR2 and anti-mouse TLR5 IgG (InvivoGen), as well as themouse IgG Invitrogen) and rat IgG (Invitrogen)
isotype controls at a final concentration of 5 mg/mL. For NLRP3 inflammasome inhibition, cells were co-treated with 1 mM MCC950
(CRID3) (Invivogen) or 100 nM IFM-2384 (IFM Therapeutics), respectively. A volume equal dimethylsulfoxid (DMSO) control, contain-
ing 0.005% DMSO was performed additionally.
Immunocytochemistry (ICC)
Primarymicroglia or ASC-deficient macrophages were seeded at a density of 23 105 cells/well in 1mL serum free DMEM in a 24-well
plate containing PLL coated coverslips. Treatments were performed as described above. After 12 h, cells were washed once with
PBS (Dulbecco) and fixed in 4% paraformaldehyde (PFA) dissolved in PBS for 15 min. For permeabilization, cells were washed three
times with PBS containing 0.1% Triton X-100 (PTX) for 5 min. Thereafter, cells were blocked using 5% normal goat serum (Vector
Laboratories) in PTX for 20 min and primary antibodies were added for another 30 min. To check for ASC speck formation, the rabbit
anti-ASC (1:250; clone AL177, AdipoGen) or mouse-specific rabbit anti-ASC/TMS1 (1:250, D2W8U, Cell Signaling Technology) and
rat anti-CD11b (1:250; Serotec by Bio-Rad) were used. After three more washing steps in PTX, the secondary antibodies goat anti-
rabbit (1:250; Invitrogen) and goat anti-rat (1:250; Invitrogen) were applied for 30 min followed by three washing steps.
40,6-Diamidino-20-phenylindol-dihydrochloride (DAPI) was used as a counterstain at 0.1 mg/mL for 20 min in PBS before coverslips
were mounted. Images were taken using a 40 X or 60 X objective. To visualize caspase-1 activity, we used the FAM-FLICA
Caspase-1 Assay Kit ImmunoChemistry Technologies LLC) according to the manufacturer’s protocol. All images were acquired
using a Nikon Eclipse Ti fluorescence 2 X microscope (Nikon). Image processing was accomplished using NIS-elements 4 (Nikon)
and Fiji ImageJ (Wayne Rusband; National Institute of Health).
Phagocytosis and Degradation of Amyloid b
Primarymicroglia were seeded at 3.53 105 cells/well in 1mL serum free DMEM in a 24-well plate. Previously, 0.5 mMFAM-labeled Ab
(Fl-Ab) (1-42) (Peptide Specialty Laboratories GmbH (PSL)) and 0.66 mM ASC were co-incubated in DMEM and kept in an incubator
under standard conditions. For phagocytosis experiments, microglia were treated with either 0.5 mM FAM-Ab or ASC-FAM-Ab com-
posites also containing 0.5 mM FAM-Ab for 15, 30 and 60 min. For cell collection, supernatants were discarded, cells were washed
with DPBS (GIBCO) and detached using 0.5% Trypsin-EDTA (GIBCO). Collected cells then were centrifuged at 300 x g for 5 min at
4C. Supernatants were again discarded and cells were blocked in 50% iFBS diluted in DPBS for 10 min on ice. Subsequently, cells
were centrifuged and pellets were resuspended in DPBS containing 2% iFBS and APC/CD11b antibody (1:100, clone M1/70,
BioLegend) for 30 min on ice. After another centrifugation step, pellets were resuspended in DBPS containing 2% iFBS, and
measured using the BD FACSCantoTM II Flow Cytometer. Detailed analysis was performed using FlowJo (FlowJo LLC/Becton Dick-
inson & Company).
For Ab degradation experiments, microglia were exposed to FAM-labeled Ab or ASC-FAM-Ab composites concentrated as
explained above for 1 h. Microglia were washed three times in PBS and subsequently incubated for 0, 1, 2, 3 or 4 h in fresh,
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FAM-Ab-free or FAM-Ab-ASC-composite-free medium. Thereafter, cells were collected and stained as described above. Degrada-
tion after 0, 1, 2, 3, and 4 h was measured using the BD FACSCantoTM II Flow Cytometer. Detailed analysis was performed using
FlowJo.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data evaluation was performed using Graph Pad Prism 7 (GraphPad Software). Data are presented as mean ± SEM in all displayed
diagrams. Every dataset is accrued from at least three independent experiments (n), containing at least two to three replicates (N).
Each dataset was analyzed for Gaussian distribution. In case of passing the normality test, one-way ANOVA or tow-way ANOVA, for
grouped datasets, were performed followed by a post hoc analysis with a Tukey test. Otherwise, non-parametric data was analyzed
using the Kruskal–Wallis test combined with a Dunn’s post hoc test. When only two groups were statistically analyzed, a t test was
performed. For non-parametric data theMann-Whitney test was applied. For each individual experiment the statistical details can be
found in the corresponding figure legends. Levels of significance are indicated as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
DATA AND CODE AVAILABILITY
This study did not generate/analyze any unique datasets or codes.
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